SCNI — Scinai Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.89m
- $5.81m
- $0.66m
- 34
- 94
- 27
- 50
Annual cashflow statement for Scinai Immunotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 20-F | 20-F |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Net Income/Starting Line | -1.3 | -12.4 | -5.8 | -6.5 | 4.8 |
| Depreciation | |||||
| Non-Cash Items | -16.3 | 7.41 | -2.3 | 1.54 | -12.8 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.25 | -3.36 | 0.271 | -4.94 | 0.019 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -21.1 | -7.58 | -7.26 | -9.38 | -6.33 |
| Capital Expenditures | -1.78 | -0.133 | -0.836 | -0.637 | -0.012 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.057 | 0.021 | — | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.73 | -0.112 | -0.836 | -0.637 | -0.012 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.99 | 21 | 6.78 | 1.09 | 3.44 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -18.3 | 13.8 | -3.3 | -9.21 | -2.92 |